Increase in Prevalence of Cancer to Drive Global Epirubicin Market

According to our new research study on "Epirubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Dosage, Application, and Distribution Channel," the market was valued at US$ 191.66 million in 2021 and is projected to reach US$ 243.99 million by 2028; it is estimated to grow at a CAGR of 3.60% from 2022 to 2028. Rising prevalence of cancer and increasing awareness about cancer are propelling the market growth. However, the elevated risk of adverse effects due to epirubicin is hampering the market's growth.

Epirubicin hydrochloride (HCl) is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are antibiotics isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became Food and Drug Administration (FDA) approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.

According to the American Cancer Society, the global burden of cancer is estimated to have risen to 19,300 new cases in 2021 and 10,000 deaths in 2020. According to stats by the institute, in the US, nearly 18,000 people were diagnosed with cancer, and about 606,520 people developed the disease in 2020. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. According to the Centers for Disease Control and Prevention (CDC), each year in the US, ~24,500 men and ~10,000 women get liver cancer, and nearly 18,600 men and 9,000 women die from the disease. The percentage of Americans who get liver cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the US. Hence, the rising prevalence of cancer cases is driving the epirubicin market.

Cancer awareness is the key to early detection and better wellbeing. Cancer is quite common in both developing and developed countries. A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization on March 8, 2021, to reduce global breast cancer mortality by 2.5% annually until 2040, thereby preventing an estimated 25,000 deaths. This initiative was presented to the global cancer community on International Women's Day by the WHO in an advocacy event, "Hearing the call of women with breast cancer." The WHO Global Initiative for Childhood Cancer was launched in September 2018. The global initiative aims to achieve a 60% survival rate for children with cancer by 2030. The WHO develops strategic action plans, led by governments and supported by individuals and groups across sectors, for achieving the goals.

World Cancer Day held every February 4, is the global uniting initiative led by the Union for International Cancer Control (UICC). Created in 2000, World Cancer Day has grown into a positive movement for everyone everywhere to unite under one voice to face one of the greatest challenges in history. They focus on raising worldwide awareness; improving education; catalyzing personal, collective, and government action; and working together to prevent cancer deaths. Therefore, various initiatives taken to increase cancer awareness are driving the epirubicin market.

Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd. are among the leading companies operating in the epirubicin market.

Based on dosage, the epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. Based on application, the market is segmented into breast cancer, liver cancer, bladder cancer, and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com